No Data
Noil Immune Biotech --- Selection of loan stocks in the Tokyo Stock Exchange Growth Market.
Noil Immune Biotech <4893> announced on the 20th that it has been selected as a borrowable stock in the Tokyo Stock Exchange's Growth Market. The company is an academia-origin biotech firm working on the practical application of next-generation cancer immunotherapy for solid tumors using its unique innovative technology, "PRIME technology," which enhances the therapeutic effects of immune cell therapy through PRIME CAR-T cells. The selection date is December 23, 2024 (Monday), and the implementation will start from the trading of that day.
Noil Immune, True Data, among others.
Revised financial estimates: forecasted consolidated ordinary profit for the first half is 0.013 billion yen, down from 0.027 billion yen, and the full-year consolidated ordinary profit forecast is 0.101 billion yen, down from 0.136 billion yen.
Noile-Immune Biotech: Notice regarding publication of earnings forecasts
Noile-Immune Biotech: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Asahi, Matsukiyo, Dentsu Group, Lancers (14th) (1379-4990)
※The above calendar is merely a schedule and may be subject to change due to the company's circumstances. --------------------------------------- November 14 (Thursday) <1379> Hokuto <1380> Akikawa Bokuen <142A> Jinjibu <1438> Gifu Landscape <1443> Giken HD <1446> Candiule <1447> SAAF HD <145A> El
Volume change rate ranking (10:00 am) - NEC, KIMOTO, etc. are ranked.
In the volume change rate ranking, you can understand the interests of market participants such as trends in trading by comparing the average volume of the past 5 days with the volume on the delivery day. ■ Top volume change rate [10:32 on October 30] (comparison of average volume of the past 5 days) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate ＜7908＞KIMOTO 59854 0118 210.44 282% 0.2663% ＜4893＞NOI
No Data